See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Stock Markets
Trade War
Social Media
Donald Trump
Natural Disasters
US Economy
Recession
Artificial Intelligence
Trade
Soccer
Published • loading... • Updated

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Larimar Therapeutics (NASDAQ:LRMR)

Summary by Benzinga
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open label extension (OLE) study Larimar is continuing to enroll adolescent patients and plans to initiate a cohort of children 2-11 years old in 1H 2025 Long-term 50 mg data from adults in OLE study and available adolescent PK run-in d…

2 Articles

All
Left
Center
1
Right
BenzingaBenzinga
Center

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Larimar Therapeutics (NASDAQ:LRMR)

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open label extension (OLE) study Larimar is continuing to enroll adolescent patients and plans to initiate a cohort of children 2-11 years old in 1H 2025 Long-term 50 mg data from adults in OLE study and available adolescent PK run-in d…

·New York, United States
Read Full Article
MyChesCoMyChesCo

Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in expanding the clinical evaluation of its investigational therapy, nomlabofusp, to younger patients. Adolescents are receiving a weight-adjusted dose equivalent to the 50 mg dose used in adults. Upon completing the PK run-in study, eligible…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Thursday, January 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Bala Cynwyd

Bala Cynwyd

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal